Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.
PSGL-1
everolimus
interstitial lung disease
nanotherapy
systemic sclerosis
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
21
02
2022
received:
29
09
2021
accepted:
11
04
2022
pubmed:
22
6
2022
medline:
24
8
2022
entrez:
21
6
2022
Statut:
ppublish
Résumé
Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc), and current therapies available are of low efficacy or high toxicity. Thus, the identification of innovative less toxic and high efficacy therapeutic approaches to ILD treatment is an urgent need. The interaction of P-selectin glycoprotein ligand-1 (PSGL-1) with P-selectin initiates leukocyte extravasation and deletion of the corresponding gene (Selplg) induces a SSc-like syndrome with high incidence of ILD in aged mice. Aged PSGL-1 KO (Selplg PSGL-1 KO mice had increased numbers of CD45+ and CD45- cells, including alveolar and interstitial macrophages, eosinophils, granulocytes and NK cells, and myofibroblasts in bronchoalveolar lavage (BAL). CD45+ and CD45- cells expressing pro-inflammatory and pro-fibrotic cytokines were also increased. Lungs from PSGL-1 KO mice showed increased immune cell infiltration and apoptosis and exacerbated interstitial and peribronchial fibrosis. Targeted nanotherapy with LipHA+Ev decreased the myofibroblasts in BAL, cells producing proinflammatory and profibrotic cytokines, and the degree of lung inflammation at histology. LipHA+Ev treatment also decreased the severity of peribronchial and interstitial lung fibrosis, from moderate to mild levels. In PSGL-1 KO mice, targeted nanotherapy with LipHA+Ev was an effective treatment for SSc-ILD, reducing the number of inflammatory and fibrotic cells in BAL and reducing inflammation and fibrosis in lungs.
Sections du résumé
BACKGROUND AND PURPOSE
Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc), and current therapies available are of low efficacy or high toxicity. Thus, the identification of innovative less toxic and high efficacy therapeutic approaches to ILD treatment is an urgent need. The interaction of P-selectin glycoprotein ligand-1 (PSGL-1) with P-selectin initiates leukocyte extravasation and deletion of the corresponding gene (Selplg) induces a SSc-like syndrome with high incidence of ILD in aged mice.
EXPERIMENTAL APPROACH
Aged PSGL-1 KO (Selplg
KEY RESULTS
PSGL-1 KO mice had increased numbers of CD45+ and CD45- cells, including alveolar and interstitial macrophages, eosinophils, granulocytes and NK cells, and myofibroblasts in bronchoalveolar lavage (BAL). CD45+ and CD45- cells expressing pro-inflammatory and pro-fibrotic cytokines were also increased. Lungs from PSGL-1 KO mice showed increased immune cell infiltration and apoptosis and exacerbated interstitial and peribronchial fibrosis. Targeted nanotherapy with LipHA+Ev decreased the myofibroblasts in BAL, cells producing proinflammatory and profibrotic cytokines, and the degree of lung inflammation at histology. LipHA+Ev treatment also decreased the severity of peribronchial and interstitial lung fibrosis, from moderate to mild levels.
CONCLUSIONS AND IMPLICATIONS
In PSGL-1 KO mice, targeted nanotherapy with LipHA+Ev was an effective treatment for SSc-ILD, reducing the number of inflammatory and fibrotic cells in BAL and reducing inflammation and fibrosis in lungs.
Substances chimiques
Cytokines
0
Membrane Glycoproteins
0
P-selectin ligand protein
0
Everolimus
9HW64Q8G6G
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4534-4548Informations de copyright
© 2022 British Pharmacological Society.
Références
Alexander, S. P., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Boison, D., Burns, K. E., Dessauer, C., Gertsch, J., Helsby, N. A., Izzo, A. A., Koesling, D., … Wong, S. S. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. British Journal of Pharmacology, 178(S1), S313-S411. https://doi.org/10.1111/bph.15542
Alexander, S. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Buneman, O. P., Cidlowski, J. A., Christopoulos, A., Davenport, A. P., Fabbro, D., Spedding, M., Striessnig, J., Davies, J. A., Ahlers-Dannen, K. E., … Zolghadri, Y. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Other Protein Targets. British Journal of Pharmacology, 178(S1), S1-S26. https://doi.org/10.1111/bph.15537
Baaten, B. J., Tinoco, R., Chen, A. T., & Bradley, L. M. (2012). Regulation of antigen-experienced T cells: Lessons from the quintessential memory marker CD44. Frontiers in Immunology, 3, 23. https://doi.org/10.3389/fimmu.2012.00023
Barnes, T. C., Spiller, D. G., Anderson, M. E., Edwards, S. W., & Moots, R. J. (2011). Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: A novel target for systemic sclerosis? Annals of the Rheumatic Diseases, 70(2), 366-372. https://doi.org/10.1136/ard.2010.133587
Campochiaro, C., & Allanore, Y. (2021). An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Arthritis Research & Therapy, 23(1), 155. https://doi.org/10.1186/s13075-021-02536-5
Chiesa, E., Dorati, R., Conti, B., Modena, T., Cova, E., Meloni, F., & Genta, I. (2018). Hyaluronic acid-decorated chitosan nanoparticles for CD44-targeted delivery of Everolimus. International Journal of Molecular Sciences, 19(8). https://doi.org/10.3390/ijms19082310
Codullo, V., Cova, E., Pandolfi, L., Breda, S., Morosini, M., Frangipane, V., Malatesta, M., Calderan, L., Cagnone, M., Pacini, C., Cavagna, L., Recalde, H., Distler, J. H. W., Giustra, M., Prosperi, D., Colombo, M., Meloni, F., & Montecucco, C. (2019). Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. Journal of Controlled Release, 310, 198-208. https://doi.org/10.1016/j.jconrel.2019.08.015
Cottin, V., & Brown, K. K. (2019). Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Research, 20(1), 13. https://doi.org/10.1186/s12931-019-0980-7
Cova, E., Colombo, M., Inghilleri, S., Morosini, M., Miserere, S., Penaranda-Avila, J., Santini, B., Piloni, D., Magni, S., Gramatica, F., Prosperi, D., & Meloni, F. (2015). Antibody-engineered nanoparticles selectively inhibit mesenchymal cells isolated from patients with chronic lung allograft dysfunction. Nanomedicine (London, England), 10(1), 9-23. https://doi.org/10.2217/nnm.13.208
Cova, E., Inghilleri, S., Pandolfi, L., Morosini, M., Magni, S., Colombo, M., Piloni, D., Finetti, C., Ceccarelli, G., Benedetti, L., Cusella, M. G., Agozzino, M., Corsi, F., Allevi, R., Mrakic-Sposta, S., Moretti, S., De Gregori, S., Prosperi, D., & Meloni, F. (2017). Bioengineered gold nanoparticles targeted to mesenchymal cells from patients with bronchiolitis obliterans syndrome does not rise the inflammatory response and can be safely inhaled by rodents. Nanotoxicology, 11(4), 534-545. https://doi.org/10.1080/17435390.2017.1317862
Durham, P. G., Hanif, S. N., Contreras, L. G., Young, E. F., Braunstein, M. S., & Hickey, A. J. (2017). Disposable Dosators for pulmonary insufflation of therapeutic agents to small animals. Journal of Visualized Experiments: Jove, (121), e55356. https://doi.org/10.3791/55356
Galandrini, R., Piccoli, M., Frati, L., & Santoni, A. (1996). Tyrosine kinase-dependent activation of human NK cell functions upon triggering through CD44 receptor. European Journal of Immunology, 26(12), 2807-2811. https://doi.org/10.1002/eji.1830261203
Ghatak, S., Markwald, R. R., Hascall, V. C., Dowling, W., Lottes, R. G., Baatz, J. E., Beeson, G., Beeson, C. C., Perrella, M. A., Thannickal, V. J., & Misra, S. (2017). Transforming growth factor beta1 (TGFbeta1) regulates CD44V6 expression and activity through extracellular signal-regulated kinase (ERK)-induced EGR1 in pulmonary fibrogenic fibroblasts. The Journal of Biological Chemistry, 292(25), 10465-10489. https://doi.org/10.1074/jbc.M116.752451
González-Tajuelo, R., de la Fuente-Fernandez, M., Morales-Cano, D., Munoz-Callejas, A., González-Sánchez, E., Silvan, J., Serrador, J. M., Cadenas, S., Barreira, B., Espartero-Santos, M., Gamallo, C., Vicente-Rabaneda, E. F., Castaneda, S., Perez-Vizcaino, F., Cogolludo, A., Jimenez-Borreguero, L. J., & Urzainqui, A. (2020). Spontaneous pulmonary hypertension associated with systemic sclerosis in P-selectin glycoprotein ligand 1-deficient mice. Arthritis & Rhematology, 72(3), 477-487. https://doi.org/10.1002/art.41100
González-Tajuelo, R., Silvan, J., Perez-Frias, A., de la Fuente-Fernandez, M., Tejedor, R., Espartero-Santos, M., Vicente-Rabaneda, E., Juarranz, A., Munoz-Calleja, C., Castaneda, S., Gamallo, C., & Urzainqui, A. (2017). P-selectin preserves immune tolerance in mice and is reduced in human cutaneous lupus. Scientific Reports, 7, 41841. https://doi.org/10.1038/srep41841
Jordan, A. R., Racine, R. R., Hennig, M. J., & Lokeshwar, V. B. (2015). The role of CD44 in disease pathophysiology and targeted treatment. Frontiers in Immunology, 6, 182. https://doi.org/10.3389/fimmu.2015.00182
Lee, S. C., Kim, K. H., Kim, O. H., Lee, S. K., & Kim, S. J. (2016). Activation of autophagy by Everolimus confers Hepatoprotection against ischemia-reperfusion injury. American Journal of Transplantation, 16(7), 2042-2054. https://doi.org/10.1111/ajt.13729
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., & Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15178
Litwiniuk, M., Krejner, A., Speyrer, M. S., Gauto, A. R., & Grzela, T. (2016). Hyaluronic acid in inflammation and tissue regeneration. Wounds, 28(3), 78-88.
Malouf, M. A., Hopkins, P., Snell, G., & Glanville, A. R. (2011). An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology, 16(5), 776-783. https://doi.org/10.1111/j.1440-1843.2011.01955.x
Meloni, F., Caporali, R., Marone Bianco, A., Paschetto, E., Morosini, M., Fietta, A. M., Bobbio-Pallavicini, F., Pozzi, E., & Montecucco, C. (2004). Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: Comparison with usual interstitial pneumonia. Annals of the Rheumatic Diseases, 63(7), 892-894. https://doi.org/10.1136/ard.2003.014019
Meyer, K. C., Raghu, G., Baughman, R. P., Brown, K. K., Costabel, U., du Bois, R. M., Drent, M., Haslam, P. L., Kim, D. S., Nagai, S., Rottoli, P., Saltini, C., Selman, M., Strange, C., & Wood, B. (2012). An official American Thoracic Society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine, 185(9), 1004-1014. https://doi.org/10.1164/rccm.201202-0320ST
Midgley, A. C., Rogers, M., Hallett, M. B., Clayton, A., Bowen, T., Phillips, A. O., & Steadman, R. (2013). Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. The Journal of Biological Chemistry, 288(21), 14824-14838. https://doi.org/10.1074/jbc.M113.451336
Mirsaeidi, M., Barletta, P., & Glassberg, M. K. (2019). Systemic sclerosis associated interstitial lung disease: New directions in disease management. Frontiers in Medicine (Lausanne), 6, 248. https://doi.org/10.3389/fmed.2019.00248
Naor, D. (2016). Editorial: Interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer. Frontiers in Immunology, 7, 39. https://doi.org/10.3389/fimmu.2016.00039
Nascimento, T. L., Hillaireau, H., Noiray, M., Bourgaux, C., Arpicco, S., Pehau-Arnaudet, G., Taverna, M., Cosco, D., Tsapis, N., & Fattal, E. (2015). Supramolecular organization and siRNA binding of hyaluronic acid-coated Lipoplexes for targeted delivery to the CD44 receptor. Langmuir, 31(41), 11186-11194. https://doi.org/10.1021/acs.langmuir.5b01979
Nunez-Andrade, N., Lamana, A., Sancho, D., Gisbert, J. P., Gonzalez-Amaro, R., Sanchez-Madrid, F., & Urzainqui, A. (2011). P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in the enteric lamina propria. The Journal of Pathology, 224(2), 212-221. https://doi.org/10.1002/path.2850
Ohkawara, Y., Tamura, G., Iwasaki, T., Tanaka, A., Kikuchi, T., & Shirato, K. (2000). Activation and transforming growth factor-beta production in eosinophils by hyaluronan. American Journal of Respiratory Cell and Molecular Biology, 23(4), 444-451. https://doi.org/10.1165/ajrcmb.23.4.3875
Pandolfi, L., Frangipane, V., Bocca, C., Marengo, A., Tarro Genta, E., Bozzini, S., Morosini, M., D'Amato, M., Vitulo, S., Monti, M., Comolli, G., Scupoli, M. T., Fattal, E., Arpicco, S., & Meloni, F. (2019). Hyaluronic acid-decorated liposomes as innovative targeted delivery system for lung fibrotic cells. Molecules, 24(18), 3291. https://doi.org/10.3390/molecules24183291
Pandolfi, L., Marengo, A., Japiassu, K. B., Frangipane, V., Tsapis, N., Bincoletto, V., Codullo, V., Bozzini, S., Morosini, M., Lettieri, S., Vertui, V., Piloni, D., Arpicco, S., Fattal, E., & Meloni, F. (2021). Liposomes loaded with Everolimus and coated with hyaluronic acid: A promising approach for lung fibrosis. International Journal of Molecular Sciences, 22(14). https://doi.org/10.3390/ijms22147743
Patrucco, F., Allara, E., Boffini, M., Rinaldi, M., Costa, C., Albera, C., & Solidoro, P. (2021). Twelve-month effects of everolimus on renal and lung function in lung transplantation: Differences in chronic lung allograft dysfunction phenotypes. Therapeutic Advances in Chronic Disease, 12, 2040622321993441. https://doi.org/10.1177/2040622321993441
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
Pérez-Frías, A., Gonzalez-Tajuelo, R., Nunez-Andrade, N., Tejedor, R., Garcia-Blanco, M. J., Vicente-Rabaneda, E., Castaneda, S., Gamallo, C., Silvan, J., Esteban-Villafruela, A., Cubero-Rueda, L., Garcia-Garcia, C., Munoz-Calleja, C., Garcia-Diez, A., & Urzainqui, A. (2014). Development of an autoimmune syndrome affecting the skin and internal organs in P-selectin glycoprotein ligand 1 leukocyte receptor-deficient mice. Arthritis & Rhematology, 66(11), 3178-3189. https://doi.org/10.1002/art.38808
Rios de la Rosa, J. M., Tirella, A., Gennari, A., Stratford, I. J., & Tirelli, N. (2017). The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages. Advanced Healthcare Materials, 6(4), 1601012. https://doi.org/10.1002/adhm.201601012
Rooney, P., Srivastava, A., Watson, L., Quinlan, L. R., & Pandit, A. (2015). Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomaterialia, 19, 66-75. https://doi.org/10.1016/j.actbio.2015.02.030
Sato, S., Hasegawa, M., & Takehara, K. (2001). Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. Journal of Dermatological Science, 27(2), 140-146. https://doi.org/10.1016/S0923-1811(01)00128-1
Silvan, J., Gonzalez-Tajuelo, R., Vicente-Rabaneda, E., Perez-Frias, A., Espartero-Santos, M., Munoz-Callejas, A., Garcia-Lorenzo, E., Gamallo, C., Castaneda, S., & Urzainqui, A. (2018). Deregulated PSGL-1 expression in B cells and dendritic cells may be implicated in human systemic sclerosis development. The Journal of Investigative Dermatology, 138(10), 2123-2132. https://doi.org/10.1016/j.jid.2018.04.003
Silver, R. M., & Wells, A. U. (2008). Histopathology and bronchoalveolar lavage. Rheumatology (Oxford), 47(Suppl 5), v62-v64. https://doi.org/10.1093/rheumatology/ken272
Solomon, J. J., Olson, A. L., Fischer, A., Bull, T., Brown, K. K., & Raghu, G. (2013). Scleroderma lung disease. European Respiratory Review, 22(127), 6-19. https://doi.org/10.1183/09059180.00005512
Steen, V. D., & Medsger, T. A. (2007). Changes in causes of death in systemic sclerosis, 1972-2002. Annals of the Rheumatic Diseases, 66(7), 940-944. https://doi.org/10.1136/ard.2006.066068
Sziksz, E., Pap, D., Lippai, R., Beres, N. J., Fekete, A., Szabo, A. J., & Vannay, A. (2015). Fibrosis related inflammatory mediators: Role of the IL-10 cytokine family. Mediators of Inflammation, 2015, 764641. https://doi.org/10.1155/2015/764641
Urzainqui, A., Martinez del Hoyo, G., Lamana, A., de la Fuente, H., Barreiro, O., Olazabal, I. M., Martin, P., Wild, M. K., Vestweber, D., Gonzalez-Amaro, R., & Sanchez-Madrid, F. (2007). Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. Journal of Immunology, 179(11), 7457-7465. https://doi.org/10.4049/jimmunol.179.11.7457
Urzainqui, A., Serrador, J. M., Viedma, F., Yanez-Mo, M., Rodriguez, A., Corbi, A. L., Alonso-Lebrero, J. L., Luque, A., Deckert, M., Vazquez, J., & Sanchez-Madrid, F. (2002). ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. Immunity, 17(4), 401-412. https://doi.org/10.1016/S1074-7613(02)00420-X
Walker, U. A., Tyndall, A., Czirjak, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., Muller-Ladner, U., Bocelli-Tyndall, C., & Matucci-Cerinic, M. (2007). Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database. Annals of the Rheumatic Diseases, 66(6), 754-763. https://doi.org/10.1136/ard.2006.062901
Zarbock, A., Ley, K., McEver, R. P., & Hidalgo, A. (2011). Leukocyte ligands for endothelial selectins: Specialized glycoconjugates that mediate rolling and signaling under flow. Blood, 118(26), 6743-6751. https://doi.org/10.1182/blood-2011-07-343566